Summary
The pharmacokinetics of the antiarrhythmic drug diprafenone have been investigated in 6 healthy volunteers following single intravenous (50 mg) and oral doses (50 and 150 mg).
Diprafenone was mainly eliminated by metabolism in the liver. Following i.v. infusion of 50 mg diprafenone, the terminal half-life of elimination was 1.50 h, the volume of distribution at steady-state was 1.23 l·kg−1, and the free fraction in plasma was 1.68%. Mean total plasma clearance was 741 ml·min−1·70 kg−1, which approaches normal liver blood flow after correction for the blood/plasma concentration ratio.
Thus, diprafenone can be classified as a high extraction drug. Following oral administration, a dose-dependent increase in bioavailability from 10.9 (50 mg dose) to 32.5% (150 mg dose) was observed.
The data suggest that diprafenone is subject to saturable hepatic first-pass metabolism.
References
Gülker H, Thale J, Olbing B, Heuer H, Frenking B, Bender F (1985) Assessment of the antiarrhythmic profile of the new class I agent diprafenone. Arzneimittelforsch/Drug Res 35: 1387–1393
Manz M, Beermann J, Gerckens U, Lüderitz B (1986) Elektrophysiologische Wirkungen von Diprafenon bei supraventrikulärer und ventrikulärer Tachykardie. Z Kardiol 75: 757–763
Heuer H, Gülker H, Hasfeld M, Frenking B, Behrenbeck T (1987) Behandlung chronischer ventrikulärer Arrhythmien mit dem neuen Klasse-Ic-Antiarrhythmikum Diprafenon — Ergebnisse der Langzeittherapie. Z Kardiol 76: 415–420
Schmidt W, Jähnchen E (1979) Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats. J Pharmacokinet Biopharm 7: 643–663
Gibaldi M, McNamara PJ (1977) Tissue binding of drugs. J Pharm Sci 66: 1211–1222
Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074
Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man. Arneimittelforsch/Drug Res 33: 763–770
Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA (1983) Clinical pharmacology of propafenone. Circulation 68: 589–596
Frabetti L, Marchesini B, Capucci A, Cavallini C, Gubelli S, Ambrosioni E, Magnani B (1986) Anti-arrhythmic efficacy of propafenone: Evaluation of effective plasma levels following single and multiple doses. Eur J Clin Pharmacol 30: 665–671
Freedman SB, Richmond DR, Ashley JJ, Kelly DT (1981) Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther 30: 644–652
Shand DG, Hammill SC, Aanonsen L, Pritchett EL (1981) Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther 30: 701–706
Schwartz JB, Keefe D, Kirsten E, Kates R, Harrison DC (1982) Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J 104: 198–203
Eichelbaum M, Somogyi A (1984) Inter- and intrasubject variations in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol 26: 47–53
Schwartz JB, Abernathy DR, Taylor AA, Mitchell JR (1985) An investigation of the cause of accumulation of verapamil during regular dosing in patients. Br J Clin Pharmacol 19: 512–516
Jähnchen E, Bechtold H, Kapser W, Kersting F, Just HJ, Heykants J, Meinertz T (1979) Loracinide I. Saturable presystemic elimination. Clin Pharmacol Ther 26: 187–195
Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1981) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol 19: 131–137
Johnston A, Burgess CD, Hamer J (1981) Systemic availability of oral verapamil and effect on PR-interval in man. Br J Clin Pharmacol 12: 397–400
McAllister RG Jr, Kirsten EB (1982) The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31: 418–426
Seipel L, Breithardt G (1980) Propafenone — a new anti-arrhythmic drug. Eur Heart J 1: 309–313
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Trenk, D., Wagner, F., Sachs, W. et al. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. Eur J Clin Pharmacol 37, 313–316 (1989). https://doi.org/10.1007/BF00679792
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00679792